MRK Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Merck & Co. (MRK) is currently trading at $93.11 as of the latest data on 2025-03-21. The stock is in a bearish trend, with the Relative Strength Index (RSI) indicating oversold conditions at 40.52 for the 6-period and 49.47 for the 12-period. The MACD line is slightly above the signal line, suggesting some bullish momentum, but the overall trend remains bearish.
News and Fundamental Analysis:
Positive News: MRK has received a high rating of 90% from Validea's Earnings Yield Investor model, indicating strong fundamentals and valuation in the Biotechnology & Drugs industry. Keytruda continues to drive growth, with sales increasing by 19% year-over-year.
Negative News: The company faces challenges due to paused Gardasil shipments to China and increased competition in diabetes drugs, which has led to a 38% decline in sales for Januvia and Janumet.
Fibonacci Levels:
The Fibonacci levels indicate resistance at $96.33 (R1) and support at $93.17 (S1). The stock is currently trading near the lower end of this range.
Analyst Sentiment:
Analysts have mixed opinions on MRK. While some maintain a Buy rating with price targets ranging from $112 to $135, others have a Hold rating with a target of $110.
Conclusion:
Based on the technical indicators and news sentiment, MRK is expected to face resistance at $96.33. The stock may pull back to the support level of $93.17 in the next trading week. The exact price prediction for the next trading week is $94.50. It is recommended to sell or wait for a clearer trend before entering the market.
MRK Similar Chart Price Prediction
The price of MRK is predicted to go up -6.99%, based on the high correlation periods with CLAR. The similarity of these two price pattern on the periods is 96.66%.
MRK
CLAR
Down: -6.99%Similarity: 96.66%
MRK Revenue Forecast
MRK EPS Forecast
MRK FAQs
What is MRK revenue forecast for next quarter？
What is MRK eps forecast for next quarter？
MRK VS S&P500
Keytruda looks best positioned in the immuno-oncology landscape, buoyed by a first-mover advantage in the important indication of first-line non-small cell lung cancer.
The growth in Merck's high margin cancer drugs should help expand the company's overall operating margin.
Merck supports a strong dividend yield that looks secure based on a wide diversified portfolio of drugs.
MRK Analyst's Forecast
Vamil Divan
Guggenheim
Strong Buy
2025-02-12
Price Target
$122 → $115
Upside
+38.07%
Guggenheim analyst Vamil Divan lowered the firm's price target on Merck to $115 from $122 and keeps a Buy rating on the shares. The firm is updating its company model following Q4 earnings and the company's initial FY25 guidance, noting that its lower target is mainly driven by lower sales estimates for Gardasil, partially offset by higher expectations on management's ability to execute on converting patients to subcutaneous Keytruda.
Terence Flynn
Morgan Stanley
Hold
2025-02-05
Price Target
$113 → $106
Upside
+18.21%
Terence Flynn
Morgan Stanley
Hold
2025-01-21
Price Target
$123 → $113
Upside
+17.41%
